Athira Pharma, Inc. — Q1 2021 Form 10-Q
Filing identity: The request metadata names Leonabio, Inc., but the filing provided is Athira Pharma, Inc. (Nasdaq: ATHA), for the quarter ended March 31, 2021, filed May 13, 2021. Confirm the intended issuer before relying on this summary.
Business context and reporting period
Athira is a clinical-stage biopharmaceutical company developing small molecules intended to enhance HGF/MET signaling and address neurodegenerative disorders. Its lead candidate, ATH-1017, is being developed primarily for mild-to-moderate Alzheimer’s disease (AD). The company had no products approved for sale and generated no product revenue.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Research and development expense | $7.445 million | $0.592 million |
| General and administrative expense | $3.336 million | $0.675 million |
| Total operating expenses | $10.781 million | $1.267 million |
| Grant income | $1.831 million | $0.022 million |
| Other income (expense), net | $0.084 million | $(0.560) million |
| Net loss | $(8.866) million | $(1.805) million |
| Net loss per share, basic and diluted | $(0.25) | $(0.48) |
| Cash used in operating activities | $7.305 million | $1.175 million |
No product sales or gross margin were reported; product margins are therefore not applicable. Q1 2021 operating expenses rose sharply as clinical development and company operations expanded. The loss per share improved despite the larger net loss, principally reflecting a substantially higher weighted-average share count after the IPO and subsequent equity issuances.
At March 31, 2021, Athira reported $127.823 million of cash and cash equivalents, $176.367 million of short-term investments, and $53.467 million of long-term investments—$357.7 million in cash, cash equivalents and investments in total. Total assets were $369.414 million, total liabilities $6.197 million, and stockholders’ equity $363.217 million. Liabilities included operating lease obligations; the company reported no outstanding convertible notes at quarter-end.
Cash increased $67.198 million during the quarter. Financing provided $97.211 million, primarily from the follow-on offering; investing used $22.708 million, primarily for purchases of available-for-sale securities. The filing reports no positive operating cash flow.
Material changes versus the prior comparable period
- Research and development expense increased $6.853 million, mainly from ATH-1017 clinical-trial start-up and clinical drug-supply costs, plus personnel growth.
- General and administrative expense increased $2.661 million, reflecting higher personnel, insurance, facilities and professional-service costs.
- Grant income increased to $1.831 million, principally from the NIH/National Institute on Aging grant; the prior-year amount was minimal.
- Other income improved by $0.644 million, as Q1 2020 included fair-value losses and convertible-note interest expense that did not recur.
- In January and February 2021, Athira sold 4.6 million shares at $22.50 per share, receiving approximately $96.8 million net. Shares outstanding were 37.15 million at quarter-end, up from 32.49 million at December 31, 2020.
Outlook, risks and other notable matters
- Management estimated that the $357.7 million of cash, cash equivalents and investments at March 31, 2021 would fund operating and capital needs through at least 2022, based on its current operating plan. The company expected losses and research and development spending to increase, and stated that substantial additional funding would be needed over time.
- LIFT-AD, a Phase 2/3 trial of ATH-1017 for mild-to-moderate AD, was underway; topline results were expected by the end of 2022. ACT-AD, a Phase 2 P300 trial, was expected to report topline results by early 2022. These are management expectations, not assured outcomes.
- Management described Phase 1a/1b ATH-1017 results as generally well tolerated, with no serious adverse events, and reported improved P300 latency in AD subjects. The filing cautions that only 11 subjects with mild-to-moderate AD were included and that a link between P300 latency and improved cognition had not been established.
- Key risks include clinical-trial failure or delay, patient enrollment and retention, uncertain regulatory approval, reliance on third-party research and manufacturing providers, competition, intellectual-property protection, and potential COVID-19 disruption to trials, sites, suppliers and operations.
- The company reported no legal proceedings it believed would have a material adverse effect and no material changes in internal control over financial reporting; management considered disclosure controls effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer mismatch: the supplied filing is for Athira Pharma, not Leonabio.
- Check subsequent LIFT-AD and ACT-AD enrollment, trial status, results and any changes to stated timelines.
- Assess whether the projected cash runway remains valid against actual clinical, manufacturing and operating spending, and whether additional financing is required.
- Review the underlying clinical data and the limitations of the small Phase 1 AD sample and P300 measure.
- Verify subsequent disclosures concerning COVID-19 impacts, third-party supply, regulatory interactions, and any material legal or intellectual-property developments.